Roivant Sciences (NASDAQ:ROIV) Stock: Insider Melissa Epperly Sells 17,750 Shares

Roivant Sciences Ltd. (NASDAQ:ROIV) Director Melissa Epperly sold 17,750 shares of the business’s stock in a transaction on Thursday, October 1st. The shares were sold at an average price of $36.10, for a total transaction of $640,775.00. Following the completion of the sale, the director owned 14,954 shares in the company, valued at $539,839.40. This represents a 54.27% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Roivant Sciences Trading Up 0.2%

Shares of Roivant Sciences stock traded up $0.06 during mid-day trading on Monday, reaching $35.78. 6,200,484 shares of the stock were exchanged, compared to its average volume of 6,424,994. The company has a market cap of $25.84 billion, a price-to-earnings ratio of -67.51 and a beta of 1.10. The firm has a 50-day simple moving average of $36.58 and a 200 day simple moving average of $32.60. Roivant Sciences Ltd. has a fifty-two week low of $15.25 and a fifty-two week high of $42.50.

Roivant Sciences (NASDAQ:ROIV) last announced its quarterly earnings results on Friday, August 7th. The company reported ($0.26) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.30) by $0.04. The firm had revenue of $1.44 million during the quarter, compared to the consensus estimate of $2.06 million. Roivant Sciences had a negative net margin of 3,534.96% and a negative return on equity of 22.94%. On average, research analysts predict that Roivant Sciences Ltd. will post -2 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several research analysts have recently commented on ROIV shares. Bank of America reissued a “neutral” rating on shares of Roivant Sciences in a report on Friday, July 31st. Cantor Fitzgerald reiterated an “overweight” rating on shares of Roivant Sciences in a research report on Thursday, September 24th. Sanford C. Bernstein raised Roivant Sciences to a “strong-buy” rating in a research note on Wednesday, July 29th. Citigroup boosted their price objective on Roivant Sciences from $42.00 to $46.00 and gave the stock a “buy” rating in a research note on Monday, August 10th. Finally, Guggenheim increased their target price on Roivant Sciences from $42.00 to $46.00 and gave the stock a “buy” rating in a report on Wednesday, September 9th. One analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, Roivant Sciences presently has a consensus rating of “Moderate Buy” and a consensus price target of $45.64.

Institutional Trading of Roivant Sciences

Several hedge funds have recently modified their holdings of the stock. Waverly Advisors LLC raised its position in Roivant Sciences by 2.3% in the 2nd quarter. Waverly Advisors LLC now owns 12,869 shares of the company’s stock worth $455,000 after purchasing an additional 291 shares during the last quarter. Fifth Third Bancorp boosted its position in Roivant Sciences by 8.7% in the 1st quarter. Fifth Third Bancorp now owns 4,686 shares of the company’s stock valued at $130,000 after buying an additional 376 shares during the last quarter. Bessemer Group Inc. boosted its position in Roivant Sciences by 21.8% in the 1st quarter. Bessemer Group Inc. now owns 2,465 shares of the company’s stock valued at $69,000 after buying an additional 441 shares during the last quarter. Fifth Third Wealth Advisors LLC increased its stake in shares of Roivant Sciences by 4.6% in the 1st quarter. Fifth Third Wealth Advisors LLC now owns 10,166 shares of the company’s stock valued at $282,000 after buying an additional 445 shares during the period. Finally, Versant Capital Management Inc increased its stake in shares of Roivant Sciences by 13.9% in the 2nd quarter. Versant Capital Management Inc now owns 3,995 shares of the company’s stock valued at $141,000 after buying an additional 487 shares during the period. 64.76% of the stock is owned by institutional investors.

Roivant Sciences Company Profile

Roivant Sciences Ltd. (NASDAQ:ROIV) is a biopharmaceutical company focused on discovering, developing and commercializing medicines for patients with serious or underserved diseases. The company operates through a network of subsidiary companies, known as “Vants,” each dedicated to specific therapeutic areas, drug candidates or commercial opportunities.

Roivant’s research and development activities have included treatments for immune-mediated diseases, rare disorders, oncology and conditions affecting the nervous system.